Last month, the Clinical Trials for Alzheimer's Disease (CTAD) conference was held in Boston. Phyllis Greenberger, Senior Vice President of Science & Health Policy, HealthyWomen, shares her experiences at the conference.
Last week was the Clinical Trials for Alzheimer’s Disease (CTAD) conference in Boston. The Alliance's Missy Jenkins and Ryne Carney were in attendance, as were those from various other organizations. We are pleased to present a post from Eric Sokol, vice president, Public Policy, the Alzheimer’s Foundation, about some of the highlights from the conference.
Last month, the Alzheimer’s Association International Conference was held in London, England. While we are still years away from discovering a cure, the conference highlights the steady efforts of researchers and scientists to better understand the devastating disease.
Researchers at the Keck School of Medicine of the University of Southern California may have discovered Alzheimer's disease in its earliest stage. Their findings provide greater insight into the disease and could offer new ways to treat the devastating disease.
On March 15, the Accelerate Cure/Treatments for Alzheimer's Disease (ACT-AD) Coalition hosted a webinar on symptomatic relief for Alzheimer's disease. An archived video of the webinar is now available.
On Wednesday, March 15, at 12 p.m. EST, the Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD) Coalition will hold a one-hour webinar on symptomatic relief for Alzheimer’s disease, featuring expert presentations.
On November 16, the ACT-AD (Accelerate Cure/Treatments for Alzheimer’s Disease) Coalition hosted its Ninth Annual FDA/Alzheimer’s Disease Allies Meeting in North Bethesda, Md., to discuss the current state of Alzheimer’s disease treatment development.
Jeanie Harris and Sharon R. Melancon had their lives changed when their 91-year-old mom, Peggy, was diagnosed with Alzheimer's disease. Here is their story of how they endured the heartache of losing their mom, found the support in the love of family, and started a community to connect their fellow Alzheimer's caregivers.
Welcome to the next edition of the Artifacts Collection. For this edition, we take another step back into our digital archives to show you the speeches of two more of our previous Annual Dinner honorees: Scott Simon and Mitchell E. Daniels Jr.
A major way the Alliance advances science is through building coalitions of diverse organizations and individuals to bring visibility and support to health research, with the ultimate goal of improving the healthy length and quality of life for everyone. Learn more.
Welcome to the next edition of the Artifacts Collection. For this edition, we take a step back into our digital archives to show you the speeches of two of our previous Annual Dinner honorees: Dr. Rudy Tanzi and Jeremy Bloom.
At last month's annual dinner, the Alliance gave eminent Harvard researcher Rudolph E. Tanzi. Ph.D., the Silver Innovator Award for spearheading his research lab’s “Alzheimer’s-in-a-dish model,” a revolutionary 3-D discovery that gives new hope for the development of therapies to treat and cure the condition.
This week the Alliance for Aging Research and the U.S. Administration on Aging (AoA) released a new white paper titled Translating Innovation to Impact: Evidence-based interventions to support people with Alzheimer's disease and their caregivers at home and in their communities.
This week’s press event announcing an immediate $50 million infusion of NIH funding to Alzheimer’s research—along with commitments to include an additional $80 million in research dollars and $26 million in services and supports in the President’s FY 2013 budget—was monumental on a number of fronts.
A group of aging and Alzheimer’s advocates will be meeting this week with the senior leadership of the National Institutes of Health (NIH) to call for an increase in funding for the National Institute on Aging (NIA). In advance of this meeting, the group has orchestrated a sign-on letter to demonstrate widespread support for $1.4 billion, an increase of $300 million, in the FY 2013 NIH Budget to support the NIA. A similar letter was generated last year and garnered more than 400 signatures.
Many of you may still have this phrase ringing in your ears if you traveled with children for any length of time this past holiday season. Representatives from the ACT-AD Coalition, chaired by the Alliance for Aging Research, heard these same words almost two years ago, not uttered from the mouths of babes, but rather by prominent officials at the Food and Drug Administration (FDA) in a conversation regarding evidence to support the use of biomarkers for Alzheimer’s disease in clinical trials for “disease-modifying” therapies.
Alzheimer’s is the only top 10 killer disease in the U.S. that cannot be prevented, cured or even treated effectively over time. One big barrier: there are not enough volunteers for experimental drug trials for Alzheimer’s disease.
This is one of the best articles on Alzheimer's I’ve seen to date. It is written by Don C. Reed, a stem cell activist in California, on the promise of current research, and on embryonic stem cells; bringing attention to a subject that is often forgotten and underfunded.
Alzheimer’s disease has taken an unfortunate step in front of the national news spotlight as of late. The last two evenings, I have seen features on the evening news highlighting the devastating effects of the disease both as a public health epidemic and as a personal, family struggle.
While most people in a recent survey said they would encourage a loved one to seek early diagnosis if they suspected Alzheimer’s disease, when faced with the reality, only a small number sought out early diagnosis.
Voters for the American Express Members Project recently chose the Alzheimer’s Disease: Early Detection Matters campaign as the project they would most like to see funded. Close to 90,000 card members cast a vote—choosing from more than 1,000 potential projects. In the end, the winner was a campaign that will educate people about the importance of early diagnosis of Alzheimer’s—receiving $1.5 million in funding.
Last week, former Supreme Court Justice Sandra Day O’Connor shared personal testimony before the Senate Special Committee on Aging about the burden of Alzheimer’s disease. O’Connor stepped down from the court in 2006 to care for her husband, who has the disease. As many people know, Alzheimer’s is an overwhelming disease-both on a personal level for families and for society.
About 10 million of the almost 45 million caregivers in the United States care for individuals with Alzheimer’s disease. Most of these caregivers are not prepared for their new role, which takes a toll on their mental and physical health. Furthermore, Alzheimer’s disease is often called a “family disease,” because the daily stress of watching a loved one slowly decline affects the whole family.
Sign up for our email newsletter, Living Longer & Loving It, for the latest information on scientific research on aging and health.